Oncolytics Biotech (ONCY) said Wednesday that Germany's Paul-Ehrlich-Institute has approved the continuation of patient enrollment in Cohort 5 of its GOBLET study.
The company said the cohort will assess pelareorep combined with modified FOLFIRINOX with or without atezolizumab in patients newly diagnosed with pancreatic ductal adenocarcinoma.
The approval, which paves the way for complete enrollment of 30 patients in Stage 1, follows a positive safety review by the Data Safety Monitoring Board that recommended the study's progression, Oncolytics Biotech said.
The company also said it will present early safety data later in January, with preliminary efficacy results anticipated in H2.
Oncolytics Biotech's shares were up nearly 7% in recent Wednesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.